Lucid Diagnostics (LUCD) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)
Lucid Diagnostics (LUCD) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | 17.54% |
| 10 | Lucid Diagnostics | 176.51 Mn | 143.11 Mn | 55,000.00 | -8.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.94% |
| Mar 31, 2026 | -13.25% |
| Dec 31, 2025 | -2.97% |
| Sep 30, 2025 | 10.18% |
| Jun 30, 2025 | 18.60% |
| Mar 31, 2025 | -43.18% |
| Dec 31, 2024 | -0.69% |
| Sep 30, 2024 | -21.15% |
| Jun 30, 2024 | -21.32% |
| Mar 31, 2024 | -70.51% |
| Dec 31, 2023 | -58.28% |
| Sep 30, 2023 | -91.55% |